Bapineuzumab would seem to be on somewhat shakier ground as a consequence of this deal. Nothing I heard from PFE suggests that they are bullish about the program.
Dimebon and bapi will very likely have synergistic effects on AD patients. I see no reason for PFE to push Dimebon unless, of course, bapi is shown to have little efficacy in P3.
Market Data 
Markets 
AI
